AQST Q2 2023 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$13M-0.2% YoY

Gross Profit

$7M50.0% margin

Operating Income

-$4M-31.8% margin

Net Income

-$6M-43.7% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+18.9%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$9M

Stock-Based Comp.

$631,000

Balance Sheet

Total Assets

$57M

Total Liabilities

$164M

Stockholders' Equity

-$107M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$13M	-0.2%
Gross Profit	$7M	$8M	-17.4%
Operating Income	-$4M	-$13M	+67.0%
Net Income	-$6M	-$16M	+64.5%

Revenue Segments

Manufacture and Supply Revenue

$12M88%

License and Royalty Revenue

$1M11%

Co-Development and Research Fees

$124,0001%

Geographic Segments

UNITED STATES

$7M55%

Non-US

$6M45%